Features

Filter

Current filters:

None

Popular Filters

1 to 25 of 41 results

Executive Q&A: Paul Higham, CEO of immatics

Executive Q&A: Paul Higham, CEO of immatics

27-05-2014

In an interview with The Pharma Letter, immatics chief executive Paul Higham discusses the company's…

BiotechnologyCancerGermanyHealth Medical Pharmaimmatics biotechnologiesImmunologyInterviewsMedicineOncologyVaccination

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

20-03-2014

As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price…

GlobalInterviewsPharmaceuticalPricing

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

14-03-2014

Health care is a human right and the pharma industry must evolve to meet future challenges, claims Elias…

EuropeHealthcareInterviewsPharmaceuticalSanofi

Pharma Summit: Rethinking the future – new business models for pharma

Pharma Summit: Rethinking the future – new business models for pharma

14-03-2014

The way pharma works needs to change with an increasing focus on collaborations, sharing data and access…

HealthcareInterviewsLundbeckPfizerPharmaceuticalPricingUK

Exclusive: Changing pharma marketplace means new dynamics to deal with, says Mundipharma executive

11-02-2014

The pharmaceutical market is changing, says Georg Toufar, chief marketing officer of Mundipharma International,…

InterviewsManagementMarkets & MarketingMundipharmaPharmaceutical

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

04-02-2014

A UK-based mobile human monitoring company is making waves in health care as it aims to revolutionize…

BiotechnologyInterviewsPharmaceuticalResearchUK

EXPERT VIEW: Pharmaceutical firms “can’t keep ignoring information risk”

28-01-2014

Knowledge is the lifeblood of the pharmaceutical sector. From raw experimental data to complex chemical…

EuropeInterviewsManagementPharmaceutical

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

1 to 25 of 41 results

Back to top